Literature DB >> 19538209

BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson's disease.

F R Guerini1, E Beghi, G Riboldazzi, R Zangaglia, C Pianezzola, G Bono, C Casali, C Di Lorenzo, C Agliardi, G Nappi, M Clerici, E Martignoni.   

Abstract

BACKGROUND AND
PURPOSE: A possible association between Parkinson's disease (PD) and the polymorphism of Brain Derived Neurotrophic Factor (BDNF) G196A (Val66Met) has been suggested by different studies that nevertheless yielded-contrasting result. The purpose of this study was to analyze such possible association in a cohort of Italian PD patients.
METHODS: The BDNF polymorphisms were analyzed in 294 Italian patients with PD; results were compared to those obtained in 233 age- and sex-matched healthy controls (HC) enrolled from two tertiary centres in Italy. Polymorphisms were determined by Restriction Fragment Length Polymorphism (RFLP) analysis; correlations between BDNF G196A polymorphism, and cognitive function were established by sub analyzing the results upon dividing PD patients based on their Mini Mental State Examination (MMSE) score.
RESULTS: Univariate analysis showed a highly significant correlation between the BDNF(AA) genotype and a MMSE score < or =24. Hence, the distribution of this genotype in PD individuals with a MMSE score < or =24 was significantly increased compared to PD patients with an MMSE score >24 and HC (P < 0.001 in both cases). Multivariate analyses showed that BDNF (AA) genotype was associated to a sixfold risk of cognitive impairment.
CONCLUSIONS: The BDNF(AA) homozygote genotype is over-represented in PD patients compared with normal individuals; this genotype was significantly correlated to cognitive impairment, age and disease severity. These results, although preliminary, could be important in establishing novel diagnostic and therapeutic approaches to PD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19538209     DOI: 10.1111/j.1468-1331.2009.02706.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  26 in total

Review 1.  Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines.

Authors:  Irene Litvan; Jennifer G Goldman; Alexander I Tröster; Ben A Schmand; Daniel Weintraub; Ronald C Petersen; Brit Mollenhauer; Charles H Adler; Karen Marder; Caroline H Williams-Gray; Dag Aarsland; Jaime Kulisevsky; Maria C Rodriguez-Oroz; David J Burn; Roger A Barker; Murat Emre
Journal:  Mov Disord       Date:  2012-01-24       Impact factor: 10.338

Review 2.  Mild cognitive impairment in Parkinson's disease.

Authors:  Saul Martinez-Horta; Jaime Kulisevsky
Journal:  J Neural Transm (Vienna)       Date:  2019-04-08       Impact factor: 3.575

3.  Evidence of associations between brain-derived neurotrophic factor (BDNF) serum levels and gene polymorphisms with tinnitus.

Authors:  Aysun Coskunoglu; Seda Orenay-Boyacioglu; Artuner Deveci; Mustafa Bayam; Ece Onur; Arzu Onan; Fethi S Cam
Journal:  Noise Health       Date:  2017 May-Jun       Impact factor: 0.867

Review 4.  MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI.

Authors:  Irene Litvan; Dag Aarsland; Charles H Adler; Jennifer G Goldman; Jaime Kulisevsky; Brit Mollenhauer; Maria C Rodriguez-Oroz; Alexander I Tröster; Daniel Weintraub
Journal:  Mov Disord       Date:  2011-06-09       Impact factor: 10.338

Review 5.  Impact of the BDNF Val66Met polymorphism on cognition: implications for behavioral genetics.

Authors:  Iva Dincheva; Charles E Glatt; Francis S Lee
Journal:  Neuroscientist       Date:  2012-02-24       Impact factor: 7.519

6.  Dosage effects of BDNF Val66Met polymorphism on cortical surface area and functional connectivity.

Authors:  Chao Wang; Yuanchao Zhang; Bing Liu; Haixia Long; Chunshui Yu; Tianzi Jiang
Journal:  J Neurosci       Date:  2014-02-12       Impact factor: 6.167

Review 7.  Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson's disease.

Authors:  Tiago Martins Rodrigues; André Jerónimo-Santos; Tiago Fleming Outeiro; Ana Maria Sebastião; Maria José Diógenes
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

Review 8.  Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.

Authors:  Cristina Politi; Cinzia Ciccacci; Giuseppe Novelli; Paola Borgiani
Journal:  Neuromolecular Med       Date:  2018-01-05       Impact factor: 3.843

9.  rsfMRI effects of KB220Z™ on neural pathways in reward circuitry of abstinent genotyped heroin addicts.

Authors:  Kenneth Blum; Yijun Liu; Wei Wang; Yarong Wang; Yi Zhang; Marlene Oscar-Berman; Andrew Smolen; Marcelo Febo; David Han; Thomas Simpatico; Frans J Cronjé; Zsolt Demetrovics; Mark S Gold
Journal:  Postgrad Med       Date:  2014-12-16       Impact factor: 3.840

Review 10.  BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases.

Authors:  Bai Lu; Guhan Nagappan; Xiaoming Guan; Pradeep J Nathan; Paul Wren
Journal:  Nat Rev Neurosci       Date:  2013-05-15       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.